ValuEngine upgraded shares of Clovis Oncology (NASDAQ:CLVS) from a sell rating to a hold rating in a report released on Friday, December 29th.
CLVS has been the subject of several other reports. Zacks Investment Research raised shares of Clovis Oncology from a hold rating to a buy rating and set a $95.00 price target for the company in a research report on Tuesday, October 17th. Cann reaffirmed a hold rating on shares of Clovis Oncology in a research report on Monday, September 11th. Oppenheimer reaffirmed a hold rating on shares of Clovis Oncology in a research report on Tuesday, October 10th. BidaskClub raised shares of Clovis Oncology from a strong sell rating to a sell rating in a research report on Saturday, December 9th. Finally, Leerink Swann reiterated an outperform rating and issued a $90.00 price target (down previously from $107.00) on shares of Clovis Oncology in a report on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the company’s stock. The company has an average rating of Buy and an average target price of $91.83.
Shares of Clovis Oncology (NASDAQ CLVS) opened at $59.01 on Friday. Clovis Oncology has a one year low of $45.42 and a one year high of $99.45. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.19 and a quick ratio of 3.16.
Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.18) by ($0.06). The firm had revenue of $16.81 million for the quarter, compared to analysts’ expectations of $21.12 million. Clovis Oncology had a negative net margin of 947.47% and a negative return on equity of 122.06%. During the same period in the previous year, the company posted ($1.70) earnings per share. analysts expect that Clovis Oncology will post -7.65 EPS for the current fiscal year.
In other Clovis Oncology news, Director Thorlef Spickschen sold 4,500 shares of the firm’s stock in a transaction on Friday, December 8th. The stock was sold at an average price of $60.00, for a total value of $270,000.00. Following the transaction, the director now owns 25,618 shares in the company, valued at approximately $1,537,080. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the firm’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $64.16, for a total value of $192,480.00. Following the completion of the transaction, the insider now owns 182,583 shares in the company, valued at approximately $11,714,525.28. The disclosure for this sale can be found here. Insiders sold a total of 18,000 shares of company stock worth $1,199,565 in the last three months. 12.50% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of CLVS. Capital Analysts LLC purchased a new position in shares of Clovis Oncology during the 3rd quarter worth $111,000. Phocas Financial Corp. purchased a new position in shares of Clovis Oncology during the 2nd quarter worth $112,000. Cypress Capital Management LLC WY raised its holdings in shares of Clovis Oncology by 272.7% during the 3rd quarter. Cypress Capital Management LLC WY now owns 2,050 shares of the biopharmaceutical company’s stock worth $169,000 after acquiring an additional 1,500 shares during the period. Advisors Asset Management Inc. raised its holdings in shares of Clovis Oncology by 160.7% during the 2nd quarter. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company’s stock worth $177,000 after acquiring an additional 1,168 shares during the period. Finally, Commonwealth Equity Services Inc purchased a new position in shares of Clovis Oncology during the 3rd quarter worth $239,000.
TRADEMARK VIOLATION NOTICE: This story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/14/clovis-oncology-clvs-upgraded-to-hold-at-valuengine.html.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.